Navigation

American Gene Technologies Hosts Celebration Event For Its First IND Submission (For HIV) To The Food and Drug Administration (FDA)

American Gene Technologies Hosts Celebration Event For Its First IND Submission (For HIV) To The Food and Drug Administration (FDA)

By AGT | Nov 6, 2019
Filed Under:

ROCKVILLE, MD, November 06, 2019 – American Gene Technologies (AGT) announced today it will host a red carpet event tonight to celebrate a significant milestone in the company’s 11-year history of scientific research in cell and gene therapy: AGT successfully submitted its Investigational New Drug (IND) application to the Food… [Read More]

IND Application Submission To FDA For Phase 1 Trial Of Genetically Modified Autologous Cell Therapy For HIV Announced by American Gene Technologies

IND Application Submission To FDA For Phase 1 Trial Of Genetically Modified Autologous Cell Therapy For HIV Announced by American Gene Technologies

By AGT | Oct 18, 2019
Filed Under:

ROCKVILLE, Md., Oct. 18, 2019 /PRNewswire/ — American Gene Technologies (AGT) announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for AGT’s lead HIV program, AGT103-T, which is potentially a single-dose, lentiviral vector-based gene therapy developed for the purpose of eliminating HIV from people infected with the disease. “Our aim is to… [Read More]

American Gene Technologies to Present at 2019 Cell & Gene Meeting on the Mesa

American Gene Technologies to Present at 2019 Cell & Gene Meeting on the Mesa

By AGT | Oct 2, 2019
Filed Under:

ROCKVILLE, Md., Oct. 01, 2019 (GLOBE NEWSWIRE) — American Gene Technologies announced today that its Chief Science Officer C. David Pauza, Ph.D. will present at the annual Cell & Gene Meeting on the Mesa to be held October 2-4 in Carlsbad, California. Organized by the Alliance for Regenerative Medicine, the… [Read More]

HIV Cure Program of American Gene Technologies Adds University of Maryland School of Medicine’s Institute of Human Virology as New Study Site to Support the Development of a Cell and Gene Therapy for HIV

HIV Cure Program of American Gene Technologies Adds University of Maryland School of Medicine’s Institute of Human Virology as New Study Site to Support the Development of a Cell and Gene Therapy for HIV

By AGT | Jul 2, 2019
Filed Under:

ROCKVILLE, Md. — American Gene Technologies (AGT), a leading gene and cell therapy company based in Rockville, MD, selected the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) as a new clinical site for its non-IND study, AGT-CS168, to collect clinical specimens from HIV… [Read More]

HIV Cure Program Patent Granted To American Gene Technologies

HIV Cure Program Patent Granted To American Gene Technologies

By AGT | May 21, 2019
Filed Under:

ROCKVILLE, Md., May 21, 2019 (GLOBE NEWSWIRE) — American Gene Technologies, a leading gene and cell therapy company based in Rockville, Md., was granted a second patent for its unique molecule, methods, and cell process for its HIV program. This patent further protects AGT’s lentiviral vector and proprietary process for generating autologous… [Read More]

AGT Launches Oncology Science Advisory Group to Accelerate Research For A Cancer Cure

AGT Launches Oncology Science Advisory Group to Accelerate Research For A Cancer Cure

By AGT | Mar 25, 2019
Filed Under:

ROCKVILLE, MD, UNITED STATES, March 25, 2019 /EINPresswire.com/ — American Gene Technologies (AGT), a leading gene and cell therapy biotech company based in Rockville, Md., has established an advisory group for the advancement of immunotherapies that activate gamma-delta (γδ) T cells to attack a variety of tumors including liver, prostate,… [Read More]

AGT Granted Fifth Patent Protecting Its Immunotherapy Cancer Cure Asset

AGT Granted Fifth Patent Protecting Its Immunotherapy Cancer Cure Asset

By AGT | Mar 21, 2019
Filed Under:

ROCKVILLE, MD, UNITED STATES, March 21, 2019 /EINPresswire.com/ — American Gene Technologies (AGT) recently was awarded a fifth immuno-oncology patent (“Methods and Composition for the Activation of Gamma Delta T cells” US10137144) to protect its lead asset in immunotherapy for cancer. This patent further validates the advances AGT has made towards the treatment… [Read More]

Second Patient Cured of HIV and The Implications for American Gene Technologies's AGT103-T

Second Patient Cured of HIV and The Implications for American Gene Technologies’s AGT103-T

By AGT | Mar 9, 2019
Filed Under:

ROCKVILLE, MD, UNITED STATES, March 8, 2019 / American Gene Technologies (AGT) is pleased to see the release of information about a second individual cured of HIV in London–recently reported in the Wall Street Journal and New York Times. The patient was treated with a bone marrow transplant from a… [Read More]

American Gene Technologies Signs Research Agreement with NIAID for Experimental HIV/AIDS Cure Strategy

American Gene Technologies Signs Research Agreement with NIAID for Experimental HIV/AIDS Cure Strategy

By AGT | Feb 14, 2019
Filed Under:

AGT signed Research Collaboration Agreement with National Institute of Allergy and Infectious Diseases for studies on AGT’s cell and gene therapy for HIV/AIDS. ROCKVILLE, MD, UNITED STATES, February 14, 2019 /EINPresswire.com/ — American Gene Technologies (AGT) recently signed a Research Collaboration Agreement with the National Institute of Allergy and Infectious… [Read More]

American Gene Technologies To Attend 2019 J.P. Morgan Healthcare Conference

American Gene Technologies To Attend 2019 J.P. Morgan Healthcare Conference

By AGT | Jan 7, 2019
Filed Under:

ROCKVILLE, MD, UNITED STATES, January 7, 2019 /EINPresswire.com/ — American Gene Technologies announced today that its Chief Executive Officer, Jeff Galvin, will attend the annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis between January 7-10 in San Francisco, California. American Gene Technologies invitation to attend the conference follows recent discussions with… [Read More]

Subscribe to Our Newsletter

Subscribe to our newsletter to keep up to date with all the latest news about AGT!

Mailchimp sidebar

Follow AGT on Social Media

Send this to a friend